Skip to main content
SpringerLink
Log in

TLR4 Polymorphisms and Expression in Solid Cancers

  • Review Article
  • Published:
Molecular Diagnosis & Therapy Aims and scope Submit manuscript

Abstract

Toll-like receptors (TLRs) are a type of pattern-recognition receptor (PRR) that are part of the innate immune system known to recognize pathogen-associated molecular patterns and thereby play a crucial role in host immune response. Among the various known TLRs, TLR4 is one of the most extensively studied PRRs expressed by immune, certain nonimmune, and tumor cells. When TLR4 binds with the bacterial lipopolysaccharide, it induces production of proinflammatory cytokines, chemokines, and effector molecules as part of the immune response. Continuous exposure to pathogens and TLR4 signaling results in chronic inflammation that may further lead to malignant transformation. TLR4 is a highly polymorphic gene, and genetic variations are known to influence host immune response, leading to dysregulation of signaling pathway, which may affect an individual’s susceptibility to various diseases, including cancer. Furthermore, TLR4 expression in different tumor types may also serve as a marker for tumor proliferation, differentiation, metastasis, prognosis, and patient survival. This review aims to summarize various reports related to TLR4 polymorphisms and expression patterns and their influences on different cancer types with a special focus on solid tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.

    CAS  PubMed  Google Scholar 

  2. Chen X, Liu F, Li B, Wei YG, Yan LN, Wen TF. P53 codon 72 polymorphism and liver cancer susceptibility: a meta-analysis of epidemiologic studies. World J Gastroenterol. 2011;17:1211–8.

    PubMed  PubMed Central  Google Scholar 

  3. Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, et al. Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol. 2006;100:173–8.

    CAS  PubMed  Google Scholar 

  4. Zhang Z, Fu G, Wang M, Tong N, Wang S, Zhang Z. P53 codon 72 polymorphism and ovarian cancer risk: a meta-analysis. J Nanjing Med Univ. 2008;22:279–85.

    Google Scholar 

  5. Izmirli M. A literature review of MTHFR (C677T and A1298C polymorphisms) and cancer risk. Mol Biol Rep. 2013;40:625–37.

    CAS  PubMed  Google Scholar 

  6. Manuguerra M, Saletta F, Karagas MR, Berwick M, Veglia F, Vineis P, et al. XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review. Am J Epidemiol. 2006;164:297–302.

    PubMed  Google Scholar 

  7. Canbay E, Eraltan IY, Cercel A, Isbir T, Gazioglu E, Aydogan F, et al. CCND1 and CDKN1B polymorphisms and risk of breast cancer. Anticancer Res. 2010;30:3093–8.

    CAS  PubMed  Google Scholar 

  8. Kibel AS, Suarez BK, Belani J, Oh J, Webster R, Brophy-Ebbers M, et al. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res. 2003;63:2033–6.

    CAS  PubMed  Google Scholar 

  9. Agundez J. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab. 2004;5:211–24.

    CAS  PubMed  Google Scholar 

  10. Chen B, Cao L, Zhou Y, Yang P, Wan HW, Jia GQ, et al. Glutathione S-transferase T1 (GSTT1) gene polymorphism and gastric cancer susceptibility: a meta-analysis of epidemiologic studies. Dig Dis Sci. 2010;55:1831–8.

    CAS  PubMed  Google Scholar 

  11. Huang S, Wu F, Luo M, Ma L, Gao K, Li J, et al. The glutathione S-transferase P1 341C>T polymorphism and cancer risk: a meta-analysis of 28 case–control studies. PLoS One. 2013;8:e56722.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Schröder NWJ, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis. 2005;5:156–64.

    PubMed  Google Scholar 

  13. Misch EA, Hawn TR. Toll-like receptor polymorphisms and susceptibility to human disease. Clin Sci. 2008;114:347–60.

    PubMed  Google Scholar 

  14. El-Omar EM, Ng MT, Hold GL. Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene. 2008;27:244–52.

    CAS  PubMed  Google Scholar 

  15. Takeda K, Akira S. Toll-like receptors. Curr Protoc Immunol. 2007;Chapter 14:Unit 14.12.

    PubMed  Google Scholar 

  16. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA. 1998;95:588–93.

    CAS  PubMed  Google Scholar 

  17. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11:373–84.

    CAS  PubMed  Google Scholar 

  18. Hashimoto C, Hudson KL, Anderson KV. The Toll gene of drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell. 1988;52:269–79.

    CAS  PubMed  Google Scholar 

  19. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/Cactus controls the potent antifungal response in Drosophila adults. Cell. 1996;86:973–83.

    CAS  PubMed  Google Scholar 

  20. Oblak A, Jerala R. Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol. 2011;2011:609579.

    PubMed  PubMed Central  Google Scholar 

  21. Miggin SM, O’Neill LAJ. New insights into the regulation of TLR signaling. J Leukoc Biol. 2006;80:220–6.

    CAS  PubMed  Google Scholar 

  22. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009;9:57–63.

    CAS  PubMed  Google Scholar 

  23. Huyton T, Rossjohn J, Wilce M. Toll-like receptors: structural pieces of a curve-shaped puzzle. Immunol Cell Biol. 2007;85:406–10.

    CAS  PubMed  Google Scholar 

  24. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801.

    CAS  PubMed  Google Scholar 

  25. McGettrick AF, O’Neill LAJ. Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. Br J Haematol. 2007;139:185–93.

    CAS  PubMed  Google Scholar 

  26. Kurt-jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol. 2000;1:398.

    CAS  PubMed  Google Scholar 

  27. Okumura A, Pitha PM, Yoshimura A, Harty RN. Interaction between Ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1. J Virol. 2010;84:27–33.

    CAS  PubMed  Google Scholar 

  28. Brattig NW, Bazzocchi C, Kirschning CJ, Reiling N, Buttner DW, Ceciliani F, et al. The major surface protein of Wolbachia endosymbionts in Filarial nematodes elicits immune responses through TLR2 and TLR4. J Immunol. 2004;173:437–45.

    CAS  PubMed  Google Scholar 

  29. Gowda DC. TLR-mediated cell signaling by malaria GPIs. Trends Parasitol. 2007;23:596–604.

    CAS  PubMed  Google Scholar 

  30. Faria MS, Calegari-Silva TC, De Carvalho Vivarini A, Mottram JC, Lopes UG, Lima APCA. Role of protein kinase R in the killing of Leishmania major by macrophages in response to neutrophil elastase and TLR4 via TNFα: and IFNβ. FASEB J. 2014;28:3050–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Tada H, Nemoto E, Shimauchi H, Watanabe T, Mikami T, Matsumoto T, et al. Saccharomyces cerevisiae -and Candida albicans-derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD14-and Toll-like receptor 4-dependent manner. Microbiol Immunol. 2002;46:503–12.

    CAS  PubMed  Google Scholar 

  32. Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med. 2010;14:2592–603.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol. 2000;164:558–61.

    CAS  PubMed  Google Scholar 

  34. Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, et al. Toll-Like Receptor 4-dependent activation of dendritic cells by -Defensin 2. Science. 2002;298:1025–9.

    CAS  PubMed  Google Scholar 

  35. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like Receptor 4. J Exp Med. 2002;195:99–111.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Vabulas RM, Braedel S, Hilf N, Singh-Jasuja H, Herter S, Ahmad-Nejad P, et al. The ER-resident heat shock protein Gp96 activates dendritic cells via the TLR2/4 pathway. J Biol Chem. 2002; 277:20847–53.

    CAS  PubMed  Google Scholar 

  37. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through Toll-Like Receptor 4. J Immunol. 2001;167:2887–94.

    CAS  PubMed  Google Scholar 

  38. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, et al. The extra domain A of fibronectin activates toll-like receptor 4. J Biol Chem. 2001;276:10229–33.

    CAS  PubMed  Google Scholar 

  39. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-Like Receptor 4. J Immunol. 2002;168:5233–9.

    CAS  PubMed  Google Scholar 

  40. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al. Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007;8:487–96.

    Google Scholar 

  41. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–9.

    CAS  Google Scholar 

  42. Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009;6:e1000010.

    PubMed Central  Google Scholar 

  43. Sanderson RD, Yang Y, Suva LJ, Kelly T. Heparan sulfate proteoglycans and heparanase—partners in osteolytic tumor growth and metastasis. Matrix Biol. 2004;23:341–52.

    CAS  PubMed  Google Scholar 

  44. Götte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 2006;66:10233–7.

    PubMed  Google Scholar 

  45. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42:145–51.

    CAS  PubMed  Google Scholar 

  46. O’Neill LAJ, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007;7:353–64.

    PubMed  Google Scholar 

  47. Gioannini TL, Teghanemt A, Zhang D, Coussens NP, Dockstader W, Ramaswamy S, et al. Isolation of an endotoxin–MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc Natl Acad Sci USA. 2004;101:4186–91.

    CAS  PubMed  Google Scholar 

  48. Tobias PS, Soldau K, Ulevitch RJ. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med. 1986;164:777–93.

    CAS  PubMed  Google Scholar 

  49. Wright SD, Tobias PS, Ulevitch RJ, Ramos RA. Lipopolysaccharide (LPS) binding protein opsonizes LPS-bearing particles for recognition by a novel receptor on macrophages. J Exp Med. 1989;170:1231–41.

    CAS  PubMed  Google Scholar 

  50. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431–3.

    CAS  PubMed  Google Scholar 

  51. Takeda K, Akira S. TLR signaling pathways. Semin Immunol. 2004;16:3–9.

    CAS  PubMed  Google Scholar 

  52. Bell JK, Mullen GED, Leifer CA, Mazzoni A, Davies DR, Segal DM. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol. 2003;24:528–33.

    CAS  PubMed  Google Scholar 

  53. Johnson CM, Lyle EA, Omueti KO, Stepensky VA, Yegin O, Alpsoy E, et al. Cutting edge: a common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol. 2007;178:7520–4.

    CAS  PubMed  Google Scholar 

  54. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;25:187–91.

    CAS  PubMed  Google Scholar 

  55. Ferwerda B, McCall M, Verheijen K, Kullberg BJ, Van der Ven A, Van der Meer J. Functional consequences of toll-like receptor 4 polymorphisms. Mol Med. 2008;14:1.

    Google Scholar 

  56. Rallabhandi P, Bell J, Boukhvalova MS, Medvedev A, Lorenz E, Arditi M, et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol. 2006;177:322–32.

    CAS  PubMed  Google Scholar 

  57. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.

    CAS  PubMed  Google Scholar 

  58. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Multhoff G, Radons J. Radiation, inflammation, and immune responses in cancer. Front Oncol. 2012;2:1–18.

    Google Scholar 

  60. Yesudhas D, Gosu V, Anwar MA, Choi S. Multiple roles of toll-like receptor 4 in colorectal cancer. Front Immunol. 2014;5:1–10.

    CAS  Google Scholar 

  61. Zare-Bidaki M, Tsukiyama-Kohara K, Kazemi Arababadi M. Toll-like receptor 4 and hepatitis B infection: molecular mechanisms and pathogenesis. Viral Immunol. 2014;27:321–6.

    CAS  PubMed  Google Scholar 

  62. Castaño-Rodríguez N, Kaakoush NO, Mitchell HM. Pattern-recognition receptors and gastric cancer. Front Immunol. 2014;5:1–23.

    Google Scholar 

  63. Skevaki C, Pararas M, Kostelidou K, Tsakris A, Routsias JG. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious diseases. Clin Exp Immunol. 2015;180:165–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Huang H, Wu J, Jin G, Zhang H, Ding Y, Hua Z, et al. A 5′-flanking region polymorphism in toll-like receptor 4 is associated with gastric cancer in a Chinese population. J Biomed Res. 2010;24:100–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Wei M. TLR4 gene polymorphisms and susceptibility to gastric carcinoma and Epstein–Barr virus-associated gastric carcinoma in Northern China. Int J Sci. 2015;1:22–30.

    Google Scholar 

  66. Santini D, Angeletti S, Ruzzo A, Dicuonzo G, Galluzzo S, Vincenzi B, et al. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol. 2008;154:360–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology. 2007;132:905–12.

    CAS  PubMed  Google Scholar 

  68. de Oliveira JG, Rossi AFT, Nizato DM, Miyasaki K, Silva AE. Profiles of gene polymorphisms in cytokines and toll-like receptors with higher risk for gastric cancer. Dig Dis Sci. 2013;58:978–88.

    CAS  PubMed  Google Scholar 

  69. Garza-Gonzalez E, Bosques-Padilla FJ, Mendoza-Ibarra SI, Flores-Gutierrez JP, Maldonado-Garza HJ, Perez-Perez GI. Assessment of the toll-like receptor 4 Asp299Gly, Thr399Ile and interleukin-8 -251 polymorphisms in the risk for the development of distal gastric cancer. BMC Cancer. 2007;7:70.

    PubMed  PubMed Central  Google Scholar 

  70. Kutikhin AG, Yuzhalin AE, Volkov AN, Zhivotovskiy AS, Brusina EB. Correlation between genetic polymorphisms within IL-1B and TLR4 genes and cancer risk in a Russian population: a case–control study. Tumor Biol. 2014;35:4821–30.

    CAS  Google Scholar 

  71. Huang L, Yuan K, Liu J, Ren X, Dong X, Tian W, et al. Polymorphisms of the TLR4 gene and risk of gastric cancer. Gene. 2014;537:46–50.

    CAS  PubMed  Google Scholar 

  72. Castaño-Rodríguez N, Kaakoush NO, Goh KL, Fock KM, Mitchell HM. The role of TLR2, TLR4 and CD14 genetic polymorphisms in gastric carcinogenesis: a case–control study and meta-analysis. PLoS One. 2013;8:e60327.

    PubMed  PubMed Central  Google Scholar 

  73. Castaño-Rodríguez N, Kaakoush NO, Pardo AL, Goh KL, Fock KM, Mitchell HM. Genetic polymorphisms in the Toll-like receptor signalling pathway in Helicobacter pylori infection and related gastric cancer. Hum Immunol. 2014;75:808–15.

    PubMed  Google Scholar 

  74. Ohara T, Morishita T, Suzuki H, Hibi T. Heterozygous Thr135Ala polymorphism at leucine-rich repeat (LRR) in genomic DNA of toll-like receptor 4 in patients with poorly-differentiated gastric adenocarcinomas. Int J Mol Med. 2006;18:59–63.

    CAS  PubMed  Google Scholar 

  75. Kupcinskas J, Wex T, Bornschein J, Selgrad M, Leja M, Juozaityte E, et al. Lack of association between gene polymorphisms of angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians. BMC Med Genet. 2011;12:112.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Hishida A, Matsuo K, Goto Y, Mitsuda Y, Hiraki A, Naito M, et al. Toll-like receptor 4 +3725 G/C polymorphism, Helicobacter pylori seropositivity, and the risk of gastric atrophy and gastric cancer in Japanese. Helicobacter. 2009;14:47–53.

    CAS  PubMed  Google Scholar 

  77. Qadri Q, Rasool R, Afroze D, Naqash S, Gulzar GM, Yousuf A, et al. Study of TLR4 and IL-8 gene polymorphisms in H. pylori-induced inflammation in gastric cancer in an ethnic kashmiri population. Immunol Investig. 2014;43:324–36.

    CAS  Google Scholar 

  78. Pimentel-Nunes P, Teixeira AL, Pereira C, Gomes M, Brandão C, Rodrigues C, et al. Functional polymorphisms of Toll-like receptors 2 and 4 alter the risk for colorectal carcinoma in Europeans. Dig Liver Dis. 2013;45:63–9.

    CAS  PubMed  Google Scholar 

  79. Landi S, Gemignani F, Bottari F, Gioia-Patricola L, Guino E, Cambray M, et al. Polymorphisms within inflammatory genes and colorectal cancer. J Negat Results Biomed. 2006;5:15.

    PubMed  PubMed Central  Google Scholar 

  80. Omrane I, Baroudi O, Kourda N, Bignon YJ, Uhrhammer N, Desrichard A, et al. Positive link between variant Toll-like receptor 4 (Asp299Gly and Thr399Ile) and colorectal cancer patients with advanced stage and lymph node metastasis. Tumor Biol. 2014;35:545–51.

    CAS  Google Scholar 

  81. Boraska Jelavić T, Barišić M, Drmic Hofman I, Boraska V, Vrdoljak E, Peruzović M, et al. Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. Clin Genet. 2006;70:156–60.

    PubMed  Google Scholar 

  82. Proença MA, de Oliveira JG, Cadamuro ACT, Succi M, Netinho JG, Goloni-Bertolo EM, et al. TLR2 and TLR4 polymorphisms influence mRNA and protein expression in colorectal cancer. World J Gastroenterol. 2015;21:7730–41.

    PubMed  PubMed Central  Google Scholar 

  83. Guo Q, Zhu J, Xia B. Polymorphism of CD14 gene but not the mutation of TLR4 gene is associated with colorectal cancer in Chinese patients. J Gastroenterol Hepatol. 2006;21:92–7.

    CAS  PubMed  Google Scholar 

  84. Tsilidis KK, Helzlsouer KJ, Smith MW, Grinberg V, Hoffman-Bolton J, Clipp SL, et al. Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control. 2009;20:1739–51.

    PubMed  PubMed Central  Google Scholar 

  85. Kopp TI, Andersen V, Tjonneland A, Vogel U. Polymorphisms in NFKB1 and TLR4 and interaction with dietary and life style factors in relation to colorectal cancer in a Danish prospective case-cohort study. PLoS One. 2015;10:1–15.

    Google Scholar 

  86. Song J, Kim DY, Kim CS, Kim HJ, Lee DH, Lee HM, et al. The association between Toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in Korean men. Cancer Genet Cytogenet. 2009;190:88–92.

    CAS  PubMed  Google Scholar 

  87. Kim HJ, Bae JS, Chang IH, Do K, Lee J, Shin HD, et al. Sequence variants of toll-like receptor 4 (TLR4) and the risk of prostate cancer in Korean men. World J Urol. 2012;30:225–32.

    CAS  PubMed  Google Scholar 

  88. Zheng SL, Augustsson-ba K, Chang B, Hedelin M, Li L, Adami H, et al. Sequence variants of Toll-Like Receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden study. Cancer Res. 2004;64:2918–22.

    CAS  PubMed  Google Scholar 

  89. Balistreri CR, Caruso C, Carruba G, Miceli V, Campisi I, Listì F, et al. A pilot study on prostate cancer risk and pro-inflammatory genotypes: pathophysiology and therapeutic implications. Curr Pharm Des. 2010;16:718–24.

    CAS  PubMed  Google Scholar 

  90. Cheng I, Plummer SJ, Casey G, Witte JS. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:352–5.

    CAS  PubMed  Google Scholar 

  91. Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ. Sequence variants of toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res. 2005;65:11771–8.

    CAS  PubMed  Google Scholar 

  92. Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, et al. Association of IL10 and other immune response and obesity related genes with prostate cancer in CLUE II. Prostate. 2009;69:874–85.

    CAS  PubMed  PubMed Central  Google Scholar 

  93. Lindström S, Hunter DJ, Grönberg H, Stattin P, Wiklund F, Xu J, et al. Sequence variants in the TLR4 and TLR6-1-10 genes and prostate cancer risk. Results based on pooled analysis from three independent studies. Cancer Epidemiol Biomarkers Prev. 2010;19:873–6.

    PubMed  PubMed Central  Google Scholar 

  94. Barrett LW, Fletcher S, Wilton SD. Regulation of eukaryotic gene expression by the untranslated gene regions and other noncoding elements. Cell Mol Life Sci. 2012;69:3613–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  95. Shen Y, Bu M, Zhang A, Liu Y, Fu B. Toll-like receptor 4 gene polymorphism downregulates gene expression and involves in susceptibility to bladder cancer. Tumor Biol. 2015;36:2779–84.

    CAS  Google Scholar 

  96. Wan B, Tan J, Zeng Q, He LY, Gan Y, Dai YB, et al. 729G/C polymorphism in Toll-like receptor 4 results in increased susceptibility to bladder cancer. Genet Mol Res. 2015;14:15482–7.

    CAS  PubMed  Google Scholar 

  97. Shen Y, Liu Y, Liu S, Zhang A. Toll-like receptor 4 gene polymorphisms and susceptibility to bladder cancer. Pathol Oncol Res. 2013;19:275–80.

    CAS  PubMed  Google Scholar 

  98. Singh V, Srivastava N, Kapoor R, Mittal RD. Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in a case–control study with bladder cancer susceptibility in a North Indian population. Arch Med Res. 2013;44:54–61.

    CAS  PubMed  Google Scholar 

  99. Pandey S, Devi R, Srivastava M, Srivastava K, Singh S, Srivastava S, et al. Gynecologic oncology impact of Toll-like receptors [TLR] 2 (−196 to −174 del) and TLR 4 (Asp299Gly, Thr399Ile) in cervical cancer susceptibility in North Indian women. Gynecol Oncol. 2009;114:501–5.

    CAS  PubMed  Google Scholar 

  100. Pandey N, Chauhan A, Raithatha N, Patel P, Desai A, Jain N. Absence of association between TLR4 Thr399Ile polymorphism and cervical cancer susceptibility. Meta Gene. 2018;17:249–55.

    Google Scholar 

  101. Zidi S, Sghaier I, Gazouani E, Mezlini A, Yacoubi-Loueslati B. Evaluation of toll-like receptors 2/3/4/9 gene polymorphisms in cervical cancer evolution. Pathol Oncol Res. 2016;22:323–30.

    CAS  PubMed  Google Scholar 

  102. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.

    CAS  PubMed  Google Scholar 

  103. Lusk MJ, Konecny P. Cervicitis: a review. Curr Opin Infect Dis. 2008;21:49–55.

    PubMed  Google Scholar 

  104. Zeljic K, Supic G, Jovic N, Kozomara R, Brankovic-Magic M, Obrenovic M, et al. Association of TLR2, TLR3, TLR4 and CD14 genes polymorphisms with oral cancer risk and survival. Oral Dis. 2014;20:416–24.

    CAS  PubMed  Google Scholar 

  105. Song C, Chen LZ, Zhang RH, Yu XJ, Zeng YX. Functional variant in the 5′-untranslated region of Toll-like receptor 4 is associated with nasopharyngeal carcinoma risk. Cancer Biol Ther. 2006;5:1285–91.

    CAS  PubMed  Google Scholar 

  106. Minmin S, Xiaoqian X, Hao C, Baiyong S, Xiaxing D, Junjie X, et al. Single nucleotide polymorphisms of toll-like receptor 4 decrease the risk of development of hepatocellular carcinoma. PLoS One. 2011;6:2–8.

    Google Scholar 

  107. Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, et al. Toll-like receptor (TLR) and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk. BMC Cancer. 2010;10:382.

    PubMed  PubMed Central  Google Scholar 

  108. Yang ZH, Dai Q, Gu YJ, Guo QX, Gong L. The Toll-like receptors polymorphisms modified cytokine and chemokines is associated with nasopharyngeal carcinoma. Cancer Sci. 2012;103:1–6.

    Google Scholar 

  109. Etokebe GE, Knežević J, Petričević B, Pavelić J, Vrbanec DZ. Single nucleotide polymorphisms in genes encoding toll-like receptor-2,-3,-4, and-9 in case–control study with breast cancer. Genet Test Mol Biomarkers. 2009;13:729–34.

    CAS  PubMed  Google Scholar 

  110. Hart K, Landvik NE, Lind H, Skaug V, Haugen A, Zienolddiny S. A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. Lung Cancer. 2011;71:123–9.

    PubMed  Google Scholar 

  111. Theodoropoulos GE, Saridakis V, Karantanos T, Michalopoulos NV, Zagouri F, Kontogianni P, et al. Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development. Breast. 2012;21:534–8.

    PubMed  Google Scholar 

  112. Yang CX, Li CY, Feng W. Toll-like receptor 4 genetic variants and prognosis of breast cancer. Tissue Antigens. 2013;81:221–6.

    CAS  PubMed  Google Scholar 

  113. Kurt H, Ozbayer C, Bayramoglu A, Gunes HV, Degirmenci İ, Oner KS, et al. Determination of the relationship between rs4986790 and rs4986791 variants of TLR4 gene and lung cancer. Inflammation. 2016;39:166–71.

    CAS  PubMed  Google Scholar 

  114. Srivastava K, Srivastava A, Kumar A, Mittal B. Significant association between toll-like receptor gene polymorphisms and gallbladder cancer. Liver Int. 2010;30:1067–72.

    CAS  PubMed  Google Scholar 

  115. Hong EP, Park JW. Sample size and statistical power calculation in genetic association studies. Genom Inf. 2012;10:117–22.

    Google Scholar 

  116. Li J, Yang F, Wei F, Ren X. The role of toll-like receptor 4 in tumor microenvironment. Oncotarget. 2017;8:66656–67.

    PubMed  PubMed Central  Google Scholar 

  117. Cammarota R, Bertolini V, Pennesi G, Bucci EO, Gottardi O, Garlanda C, et al. The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med. 2010;8:112.

    PubMed  PubMed Central  Google Scholar 

  118. Schmaußer B, Andrulis M, Endrich S, Lee SK, Josenhans C, Müller-Hermelink HK, et al. Expression and subcellular distribution of toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol. 2004;136:521–6.

    PubMed  PubMed Central  Google Scholar 

  119. Zarember KA, Godowski PJ. Tissue expression of human Toll-Like Receptors and differential regulation of Toll-Like Receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol. 2002;168:554–61.

    CAS  PubMed  Google Scholar 

  120. Furrie E, Macfarlane S, Thomson G, Macfarlane GT. Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology. 2005;115:565–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  121. Guillot L, Medjane S, Le-Barillec K, Balloy V, Danel C, Chignard TM. Response of human pulmonary epithelial cells to LPS involves Toll-like Receptor 4 (TLR4)-dependent signaling pathways. J Biol Chem. 2004;279:2712–8.

    CAS  PubMed  Google Scholar 

  122. Pivarcsi A, Bodai L, Réthi B, Kenderessy-Szabó A, Koreck A, Széll M, et al. Expression and function of Toll-like receptors 2 and 4 in human keratinocytes. Int Immunol. 2003;15:721–30.

    CAS  PubMed  Google Scholar 

  123. Bowman CC, Rasley A, Tranguch SL, Marriott I. Cultured astrocytes express toll-like receptors for bacterial products. Glia. 2003;43:281–91.

    PubMed  Google Scholar 

  124. Pioli PA, Amiel E, Schaefer TM, Connolly JE, Guyre PM. Differential expression of toll-like receptors 2 and 4 in tissues of the human female reproductive tract. Society. 2004;72:5799–806.

    CAS  Google Scholar 

  125. Schmaußer B, Andrulis M, Endrich S, Müller-Hermelink HK, Eck M. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol. 2005;295:179–85.

    PubMed  Google Scholar 

  126. Fernandez-garcia B, Eiro N, Gonza S, Aguirre A, Gonza LO, Casar M, et al. Clinical significance of Toll-like Receptor 3, 4, and 9 in gastric cancer. J Immunother. 2014;37:77–83.

    CAS  PubMed  Google Scholar 

  127. Pimentel-Nunes P, Afonso L, Lopes P, Roncon-Albuquerque R, Gonçalves N, Henrique R, et al. Increased expression of toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol Oncol Res. 2011;17:677–83.

    CAS  PubMed  Google Scholar 

  128. Yuan X, Zhou Y, Wang W, Li J, Xie G, Zhao Y, et al. Activation of TLR4 signaling promotes gastric cancer progression by inducing mitochondrial ROS production. Cell Death Dis. 2013;4:e794.

    CAS  PubMed  PubMed Central  Google Scholar 

  129. Chen G, Xu M, Chen J, Hong L, Lin W, Zhao S, et al. Clinicopathological features and increased expression of toll-like receptor 4 of gastric cardia cancer in a high-risk Chinese population. J Immunol Res. 2018;2018:7132868.

    PubMed  PubMed Central  Google Scholar 

  130. Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, et al. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer. 2010;102:908–15.

    CAS  PubMed  PubMed Central  Google Scholar 

  131. Xu H, Wu Q, Dang S, Jin M, Xu J, Cheng Y, et al. Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma. PLoS One. 2011;6:1–11.

    Google Scholar 

  132. Lu CC, Kuo HC, Wang FS, Jou MH, Lee KC, Chuang JH. Upregulation of TLRs and IL-6 as a marker in human colorectal cancer. Int J Mol Sci. 2014;16:159–77.

    PubMed  PubMed Central  Google Scholar 

  133. Simiantonaki N, Kurzik-Dumke U, Karyofylli G, Jayasinghe C, Michel-Schmidt R, Kirkpatrick CJ. Reduced expression of TLR4 is associated with the metastatic status of human colorectal cancer. Int J Mol Med. 2007;20:21–9.

    CAS  PubMed  Google Scholar 

  134. Paarnio K, Väyrynen S, Klintrup K, Ohtonen P, Mäkinen MJ, Mäkelä J, et al. Divergent expression of bacterial wall sensing toll-like receptors 2 and 4 in colorectal cancer. World J Gastroenterol. 2017;23:4831–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  135. Nihon-Yanagi Y, Terai K, Murano T, Matsumoto T, Okazumi S. Tissue expression of Toll-like receptors 2 and 4 in sporadic human colorectal cancer. Cancer Immunol Immunother. 2012;61:71–7.

    CAS  PubMed  Google Scholar 

  136. Tchórzewski M, Lewkowicz P, Dziki A, Tchórzewski H. Expression of toll-like receptors on human rectal adenocarcinoma cells. Arch Immunol Ther Exp. 2014;62:247–51.

    Google Scholar 

  137. Doan HQ, Bowen KA, Jackson LA, Evers BM. Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Res. 2009;29:2473–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  138. Eiro N, Gonzalez L, Gonzalez LO, Fernandez-Garcia B, Andicoechea A, Barbon E, et al. Toll-like receptor-4 expression by stromal fibroblasts is associated with poor prognosis in colorectal cancer. J Immunother. 2013;36:342–9.

    CAS  PubMed  Google Scholar 

  139. Hasimu A, Ge L, Li QZ, Zhang RP, Guo X. Expressions of Toll-like receptors 3, 4, 7, and 9 in cervical lesions and their correlation with HPV16 infection in Uighur women. Chin J Cancer. 2011;30:344–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  140. Wang Y, Weng Y, Shi Y, Xia X, Wang S, Duan H. Expression and functional analysis of Toll-like receptor 4 in human cervical carcinoma. J Membr Biol. 2014;247:591–9.

    CAS  PubMed  Google Scholar 

  141. Zhang H, Zhang S. The expression of Foxp3 and TLR4 in cervical cancer: association with immune escape and clinical pathology. Arch Gynecol Obstet. 2017;295:705–12.

    CAS  PubMed  Google Scholar 

  142. Werner J, Decarlo CA, Escott N, Zehbe I, Ulanova M. Expression of integrins and Toll-like receptors in cervical cancer: effect of infectious agents. Innate Immun. 2012;18:55–69.

    CAS  PubMed  Google Scholar 

  143. Yu L, Wang L, Li M, Zhong J, Wang Z, Chen S. Expression of toll-like receptor 4 is down-regulated during progression of cervical neoplasia. Cancer Immunol Immunother. 2010;59:1021–8.

    CAS  PubMed  Google Scholar 

  144. Allhorn S, Böing C, Koch AA, Kimmig R, Gashaw I. TLR3 and TLR4 expression in healthy and diseased human endometrium. Reprod Biol Endocrinol. 2008;6:1–11.

    Google Scholar 

  145. Chen X, Zhao F, Zhang H, Zhu Y, Wu K, Tan G. Significance of TLR4/MyD88 expression in breast cancer. Int J Clin Exp Pathol. 2015;8:7034–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  146. Yang H, Wang B, Wang T, Xu L, He C, Wen H, et al. Toll-like receptor 4 prompts human breast cancer cells invasiveness via lipopolysaccharide stimulation and is overexpressed in patients with lymph node metastasis. PLoS One. 2014;9:1–11.

    Google Scholar 

  147. Mehmeti M, Allaoui R, Bergenfelz C, Saal LH, Ethier SP, Johansson ME, et al. Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. Breast Cancer Res. 2015;17:130.

    PubMed  PubMed Central  Google Scholar 

  148. Ma FJ, Liu ZB, Hu X, Ling H, Li S, Wu J, et al. Prognostic value of myeloid differentiation primary response 88 and toll-like receptor 4 in breast cancer patients. PLoS One. 2014;9:e111639.

    PubMed  PubMed Central  Google Scholar 

  149. Wang X, Yu X, Wang Q, Lu Y, Chen H. Expression and clinical significance of SATB1 and TLR4 in breast cancer. Oncol Lett. 2017;14:3611–5.

    PubMed  PubMed Central  Google Scholar 

  150. Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, et al. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res. 2010;29:92.

    PubMed  PubMed Central  Google Scholar 

  151. Zhao Y, Kong X, Li X, Yan S, Yuan C, Hu W, et al. Metadherin mediates lipopolysaccharide-induced migration and invasion of breast cancer cells. PLoS One. 2011;6:e17582.

    Google Scholar 

  152. Rajput S, Volk-Draper LD, Ran S. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther. 2013;12:1676–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  153. González-Reyes S, Marín L, González L, González LO, del Casar JM, Lamelas ML, González-Quintana JMVF. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer. 2010;10:665.

    PubMed  PubMed Central  Google Scholar 

  154. Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E, et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene. 2009;28:4353.

    CAS  PubMed  PubMed Central  Google Scholar 

  155. Luo XZ, He QZ, Wang K. Expression of Toll-like receptor 4 in ovarian serous adenocarcinoma and correlation with clinical stage and pathological grade. Int J Clin Exp Med. 2015;8:14323–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  156. Kim KH, Jo MS, Suh DS, Yoon MS, Shin DH, Lee JH, et al. Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers. World J Surg Oncol. 2012;10:193.

    PubMed  PubMed Central  Google Scholar 

  157. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006;66:3859–68.

    CAS  PubMed  Google Scholar 

  158. Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF. Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother. 2009;58:1375–85.

    CAS  PubMed  Google Scholar 

  159. Woods DC, White YA, Dau CJAL. TLR4 activates NF-κB in human ovarian granulosa tumor cells. Biochem Biophys Res Commun. 2011;409:675–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  160. Wang AC, Su QB, Wu FX, Zhang XL, Liu PS. Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells. Eur J Clin Investig. 2009;39:157–64.

    CAS  Google Scholar 

  161. Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, et al. MyD88 and TLR4 expression in epithelial ovarian cancer. Mayo Clin Proc. 2018;93:307–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  162. Szczepanski M, Stelmachowska M, Stryczynski L, Golusinski W, Samara H, Mozer-Lisewska I, et al. Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma. Eur Arch Otorhinolaryngol. 2007;264:525–30.

    PubMed  Google Scholar 

  163. Ilmarinen T, Hagström J, Haglund C, Auvinen E, Leivo I, Pitkäranta A, et al. Low expression of nuclear toll-like receptor 4 in laryngeal papillomas transforming into squamous cell carcinoma. Otolaryngol Head Neck Surg. 2014;151:785–90.

    PubMed  Google Scholar 

  164. Starska K, Forma E, Bryś M, Głowacka E, Lewy-Trenda I, Lukomski M, et al. The expression of TLR pathway molecules in peripheral blood mononuclear cells and their relationship with tumor invasion and cytokine secretion in laryngeal carcinoma. Adv Med Sci. 2012;56:1–12.

    Google Scholar 

  165. Eiró N, Altadill A, Juárez LM, Rodríguez M, González LO, Atienza S, et al. Toll-like receptors 3, 4 and 9 in hepatocellular carcinoma: relationship with clinicopathological characteristics and prognosis. Hepatol Res. 2014;44:769–78.

    PubMed  Google Scholar 

  166. Liu WT, Jing YY, Yu GF, Han ZP, Yu DD, Fan QM, et al. Toll like receptor 4 facilitates invasion and migration as a cancer stem cell marker in hepatocellular carcinoma. Cancer Lett. 2015;358:136–43.

    CAS  PubMed  Google Scholar 

  167. Soares JB, Pimentel-Nunes P, Afonso L, Rolanda C, Lopes P, Roncon-Albuquerque R, et al. Increased hepatic expression of TLR2 and TLR4 in the hepatic inflammation-fibrosis-carcinoma sequence. Innate Immun. 2012;18:700–8.

    PubMed  Google Scholar 

  168. Sheyhidin I, Nabi G, Hasim A, Zhang RP, Ainiwaer J, Ma H, et al. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17:3745–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  169. Verbeek RE, Siersema PD, Ten Kate FJ, Fluiter K, Souza RF, Vleggaar FP, et al. Toll-like receptor 4 activation in Barrett’s esophagus results in a strong increase in COX-2 expression. J Gastroenterol. 2014;49:1121–34.

    CAS  PubMed  Google Scholar 

  170. Yang J, Liu D, Khatri KS, Wang J, Zhang G, Meng C, et al. Prognostic value of toll-like receptor 4 and nuclear factor-κBp65 in oral squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(753–764):e1.

    Google Scholar 

  171. Gatti G, Quintar AA, Andreani V, Nicola JP, Maldonado CA, Masini-Repiso AM, et al. Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer. Prostate. 2009;69:1387–97.

    CAS  PubMed  Google Scholar 

  172. González-Reyes S, Fernández JM, González LO, Aguirre A, Suárez A, González JM, et al. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother. 2011;60:217–26.

    PubMed  Google Scholar 

  173. Hua D, Liu M, Cheng Z, Qin X, Zhang H, Chen Y, et al. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol. 2009;46:2876–84.

    CAS  PubMed  Google Scholar 

  174. Damasdi M, Kovacs K, Farkas N, Jakab FKG. Down-regulation of Toll-like Receptor TLR4 is associated with HPV DNA integration in penile carcinoma. Anticancer Res. 2017;37:5515–9.

    PubMed  Google Scholar 

  175. Alvarado AG, Thiagarajan PS, Mulkearns-Hubert EE, Silver DJ, Hale JS, Alban TJ, et al. Glioblastoma cancer stem cells evade innate immune suppression of self-renewal through reduced TLR4 expression. Cell Stem Cell. 2017;20(450–461):e4.

    Google Scholar 

  176. Climate B, Dyck V, Phylogenies TF, Compare EP, Singh SK, Hawkins C, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401.

    Google Scholar 

  177. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–60.

    CAS  PubMed  Google Scholar 

  178. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SGPL. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488:522–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  179. Ahmed S, Moawad M, Elhefny R, Abdullatif M. Is toll like receptor 4 a common pathway hypothesis for development of lung cancer and idiopathic pulmonary fibrosis? Egypt J Chest Dis Tuberc. 2016;65:289–94.

    Google Scholar 

  180. Zhang YB, He FL, Fang M, Hua TF, Hu BD, Zhang ZH, et al. Increased expression of Toll-like receptors 4 and 9 in human lung cancer. Mol Biol Rep. 2009;36:1475–81.

    CAS  PubMed  Google Scholar 

  181. Samara KD, Antoniou KM, Karagiannis K, Margaritopoulos G, Lasithiotaki I, Koutala E, et al. Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis. Int J Oncol. 2012;40:1397–404.

    CAS  PubMed  Google Scholar 

  182. He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 2007;44:2850–9.

    CAS  PubMed  Google Scholar 

  183. Fu H, Li C, Yang W, Gai X, Jia T, Lei Y, et al. FOXP3 and TLR4 protein expression are correlated in non-small cell lung cancer: implications for tumor progression and escape. Acta Histochem. 2013;115:151–7.

    CAS  PubMed  Google Scholar 

  184. Awasthi S. Toll-like receptor-4 modulation for cancer immunotherapy. Front Immunol. 2014;5:1–5.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. P D Patel Institute of Applied Sciences, Charotar University of Science and Technology (CHARUSAT), Changa, Anand, 388421, India

    Nilesh Pandey, Alex Chauhan & Neeraj Jain

Authors
  1. Nilesh Pandey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alex Chauhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neeraj Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neeraj Jain.

Ethics declarations

Conflict of interest

Nilesh Pandey, Alex Chauhan and Neeraj Jain have no conflicts of interest that are directly relevant to the content of this article.

Funding

No sources of funding were used to conduct this study or prepare this manuscript.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 381 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pandey, N., Chauhan, A. & Jain, N. TLR4 Polymorphisms and Expression in Solid Cancers. Mol Diagn Ther 22, 683–702 (2018). https://doi.org/10.1007/s40291-018-0361-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40291-018-0361-9

Search

Navigation